DDInter1115 DDInter1676
Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the specifications of oral administration of a maximum concentration of 237 mg. It is also considered as an active ingredient in over-the-counter products.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Magnesium citrate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Linaclotide
Magnesium citrate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Arsenic trioxide
Magnesium citrate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Entrectinib
Magnesium citrate {u} may lead to a major life threatening interaction when taken with {v} Dolutegravir
Magnesium citrate {u} may lead to a major life threatening interaction when taken with {v} Bictegravir
Magnesium citrate may cause a minor interaction that can limit clinical effects when taken with Linaclotide
Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Arsenic trioxide
Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Magnesium citrate may lead to a major life threatening interaction when taken with Dolutegravir
Magnesium citrate may lead to a major life threatening interaction when taken with Bictegravir